Dr. Abdallah has served as a consultant and speaker on advisory boards for Freedom Biosciences, Douglas Pharmaceutical, Aptinyx, Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint, and FSV7. Additionally, he has filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (August 20, 2018). Dr. Averill is a consultant for Guidepoint. Dr. Krystal is a consultant for Aptinyx, Inc., Atai Life Sciences, AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited (United Kingdom), Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, and Taisho Pharmaceutical Co., Ltd. Dr. Krystal also serves on the scientific advisory boards for Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC, EpiVario, Inc., Eisai, Inc., Lohocla Research Corporation, Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., RBNC Therapeutics, Inc., Tempero Bio, Inc., and Terran Biosciences, Inc. He holds stock in Biohaven Pharmaceuticals, Sage Pharmaceuticals, and Spring Care, Inc. He has stock options in Biohaven Pharmaceuticals Medical Sciences, EpiVario, Inc., RBNC Therapeutics, Inc., Terran Biosciences, Inc., and Tempero Bio, Inc. He earns over $10,000 as the Editorial Board Editor for Biological Psychiatry. Dr. Krystal’s patents and inventions include Dopamine and noradrenergic reuptake inhibitors in the treatment of schizophrenia (US Patent #: 5,447,948, September 5, 1995), Glutamate Modulating Agents in the Treatment of Mental Disorders (US Patent No. 8,778,979 B2, July 15, 2014, US Patent Application No. 15/695,164, September 5, 2017), Intranasal Administration of Ketamine to Treat Depression (United States Patent Number: 9592207, March 14, 2017, licensed to Janssen Research & Development), Methods for Treating Suicidal Ideation (Patent Application No. 15/379,013, December 14, 2016, Yale University Office of Cooperative Research), Composition and methods to treat addiction (Provisional Use Patent Application no. 61/973/961, April 2, 2014, Yale University Office of Cooperative Research), Treatment Selection for Major Depressive Disorder (USPTO docket number Y0087.70116US00, June 3, 2016, Yale University), Compounds, Compositions, and Methods for Treating or Preventing Depression and Other Diseases (U.S. Provisional Patent Application No. 62/444,552, January 10, 2017, Yale University Office of Cooperative Research OCR 7088 US01), and Combination Therapy for Treating or Preventing Depression or Other Mood Diseases (U.S. Provisional Patent Application No. 62/719,935, August 20, 2018, Yale University Office of Cooperative Research OCR 7451 US01). Non-federal research support includes AstraZeneca Pharmaceuticals providing Saracatinib for research related to the NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4]” and Novartis providing Mavoglurant for research related to the same grant. All other co-authors declare no conflict of interest.
PubMed
Psychedelic Science